Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 2.26 | 1.93 |
NAV | ₹287.28 | ₹432.69 |
Fund Started | 01 Aug 2005 | 04 Jun 1999 |
Fund Size | ₹1098.70 Cr | ₹3849.24 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 16.38% | 17.15% |
3 Year | 26.04% | 28.32% |
5 Year | 21.93% | 23.97% |
1 Year
3 Year
5 Year
Equity | 98.90% | 96.98% |
Cash | 1.09% | 2.94% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 10.08% |
Cipla Ltd. | 5.48% |
Ajanta Pharma Ltd. | 4.92% |
Procter & Gamble Health Ltd. | 4.30% |
Dr. Reddy's Laboratories Ltd. | 4.20% |
Glenmark Pharmaceuticals Ltd. | 3.99% |
Lupin Ltd. | 3.53% |
Apollo Hospitals Enterprise Ltd. | 3.49% |
Divi's Laboratories Ltd. | 3.47% |
Fortis Healthcare Ltd. | 3.36% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.19% |
Divi's Laboratories Ltd. | 7.78% |
Max Healthcare Institute Ltd. | 6.96% |
Lonza Group Ag | 4.76% |
Cipla Ltd. | 4.69% |
Lupin Ltd. | 4.23% |
Mankind Pharma Ltd. | 3.37% |
Abbott India Ltd. | 3.34% |
Fortis Healthcare Ltd. | 3.30% |
Aster DM Healthcare Ltd. | 3.25% |
Name | Kamal Gada | Tanmaya Desai |
Start Date | 02 May 2022 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 01 Aug 2005 | 04 Jun 1999 |
Description
Launch Date